suPARnostic® eliminates doubt and supports your clinical decisions to discharge or admit patients based on prognostic evidence.
Implementing suPARnostic® in acute clinical care allows you to identify 34% * more non-acute patients. This supports the decision to discharge patients,thereby reducing crowding and readmissions, leading to lower healthcare costs.
* Ref. 2016 EMJ Rasmussen et al.
Avoid unnecessary hospitalisation
suPAR is a prognostic biomarker that reflects the extent of activation of the immune system non-specific to any individual disease.
The suPAR level is directly linked to morbidity and mortality across diseases and can therefore be used to assess the mortality of patients in the emergency department.
Implementing suPARnostic leads to fewer non-acute patients being admittedand more patients being safely discharged.
How to interpret suPAR results
suPAR level < 4 ng/ml
Supports patient discharge
suPAR level > 6 ng/ml
Supports patient hospitalisation
Improve patient outcomes and lower healthcare costs
Prognostic, data-based risk stratification increases the efficiency of the emergency department and improves patient outcomes.
Implementing suPARnostic® shortens the average patient length-of-stay by 6%* per patient and reduce crowding and hospital costs.*
* Schultz et al. Disease Markers, 2019, 10;1-8
“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”
– MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen
NEW STUDY: early anakinra treatment for COVID-19 guided by suPAR saves lives
Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.